Press release
November 13, 2025
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corp (ABUS)
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025 Additional analysis of imdusiran (AB-729) clinical